Using meta-regression modeling, we quantified the association between 15 individual MACE components and dyslipidemia biomarkers, based on 54 clinical trials of statins and PCSK9 inhibitors, which amounted to 270,471 subjects in total. This evidence concerns the gene PCSK9 and metabolic syndrome.